Pre-made Cinpanemab benchmark antibody ( Whole mAb, anti-SNCA therapeutic antibody, Anti-NACP/PARK1/PARK4/PD1 Antibody) for drug discovery and mechanism of action (MOA) research

Cat No.: GMP-Bios-ab-106

Pre-Made Cinpanemab biosimilar, Whole mAb, Anti-SNCA Antibody: Anti-NACP/PARK1/PARK4/PD1 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Cinpanemab (BIIB 054), a monoclonal antibody against pathologic alpha-synuclein aggregates, is being developed by Biogen, for the treatment of Parkinson's disease.

Order information


* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No. Package List Price(In USD) Discount off Discount Price
GMP-Bios-ab-106-1mg 1mg 3090 30% 2163

Size: 1mg | 10mg | 100mg



Description

Products Name (INN Index) Pre-Made Cinpanemab biosimilar, Whole mAb, Anti-SNCA Antibody: Anti-NACP/PARK1/PARK4/PD1 therapeutic antibody
INN Name Cinpanemab
TargetSNCA
FormatWhole mAb
Derivation
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCLambda
Highest_Clin_Trial (Jan '20)Phase-II
Est. StatusDiscontinued
100% SI Structure6ct7:HL:AB
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2018
Year Recommended2019
CompaniesNeurimmune Therapeutics;Biogen
Conditions Approvedna
Conditions Activena
Conditions Discontinuedna
Development Techna